Ranibizumab treats proliferative diabetic retinopathy more effectively than laser photocoagulation, researchers reported at the 17th EURETINA Congress. The finding challenges lasers as the standard of care, opening the door to wider use of anti-vascular endothelial growth factor (VEGF) drugs, Gabrielle Lang, MD, from the University of Ulm, Germany, told Medscape Medical News.
"VEGF inhibitors are a good option to treat proliferative diabetic retinopathy as monotherapy," she said. "I think clinicians will be able to use it."
Although laser treatments can slow the progression of proliferative diabetic retinopathy, they often cause some permanent vision loss. A handful of preliminary studies have suggested effectiveness of anti-VEGF drugs, which are widely used in the related condition of diabetic macular edema.